In Vitro Evaluation of the Antiviral Activity of Methylene Blue Alone or in Combination against SARS-CoV-2.
In Vitro Evaluation of the Antiviral Activity of Methylene Blue Alone or in Combination against SARS-CoV-2.
复制标题
DOI：
10.3390/jcm10143007
复制
发表时间：
2021-07-06
影响因子：
3.9
通讯作者：
Pradines B
中科院分区：
文献类型：
--
作者：
Gendrot M;Jardot P;Delandre O;Boxberger M;Andreani J;Duflot I;Le Bideau M;Mosnier J;Fonta I;Hutter S;La Scola B;Pradines B
2019年12月在中国武汉出现的新型严重急性呼吸综合征冠状病毒（SARS-CoV-2）导致的冠状病毒病2019 （COVID-19）已蔓延至全球。目前，官方推荐的针对SARS-CoV-2的治疗方法很少。迫切需要立即确定副作用有限、可负担得起的有效、低成本抗病毒药物。亚甲基蓝是一种合成的噻嗪染料，可能是一种潜在的抗病毒药物。研究了亚甲基蓝单独使用或与几种抗疟药物或瑞德西韦联合使用对两种临床分离的SARS-CoV-2菌株（IHUMI-3和IHUMI-6）感染的Vero E6细胞的抗病毒活性。对病毒进入细胞和进入后的影响也进行了研究。感染48 h后，RT-PCR检测病毒复制量。亚甲基蓝对IHUMI-3的中位有效浓度（EC50）和90%有效浓度（EC90）分别为0.41±0.34µM和1.85±1.41µM；分别为1.06±0.46µM和5.68±1.83µM。在获取羟氯喹的Vero E6细胞中，亚甲基蓝在SARS-CoV-2感染的进入和进入后阶段都相互作用。亚甲基蓝与奎宁、甲氟喹和吡啶的作用是叠加的。亚甲基蓝与氯喹、羟氯喹、去乙基氨基二喹、哌喹、氟苯曲明、亚铁喹、双氢青蒿素和瑞德西韦联用为拮抗剂。这些结果支持亚甲蓝治疗COVID-19的潜在兴趣。
A new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19), which emerged in Wuhan, China in December 2019, has spread worldwide. Currently, very few treatments are officially recommended against SARS-CoV-2. Identifying effective, low-cost antiviral drugs with limited side effects that are affordable immediately is urgently needed. Methylene blue, a synthesized thiazine dye, may be a potential antiviral drug. Antiviral activity of methylene blue used alone or in combination with several antimalarial drugs or remdesivir was assessed against infected Vero E6 cells infected with two clinically isolated SARS-CoV-2 strains (IHUMI-3 and IHUMI-6). Effects both on viral entry in the cell and on post-entry were also investigated. After 48 h post-infection, the viral replication was estimated by RT-PCR. The median effective concentration (EC50) and 90% effective concentration (EC90) of methylene blue against IHUMI-3 were 0.41 ± 0.34 µM and 1.85 ± 1.41 µM, respectively; 1.06 ± 0.46 µM and 5.68 ± 1.83 µM against IHUMI-6. Methylene blue interacted at both entry and post-entry stages of SARS-CoV-2 infection in Vero E6 cells as retrieved for hydroxychloroquine. The effects of methylene blue were additive with those of quinine, mefloquine and pyronaridine. The combinations of methylene blue with chloroquine, hydroxychloroquine, desethylamodiaquine, piperaquine, lumefantrine, ferroquine, dihydroartemisinin and remdesivir were antagonist. These results support the potential interest of methylene blue to treat COVID-19.
登录
查看更多内容
影响因子：
8.8
作者：
Dittmar M;Lee JS;Whig K;Segrist E;Li M;Kamalia B;Castellana L;Ayyanathan K;Cardenas-Diaz FL;Morrisey EE;Truitt R;Yang W;Jurado K;Samby K;Ramage H;Schultz DC;Cherry S
通讯作者：
Cherry S
亚甲蓝在体外抑制 SARS-CoV-2 的复制。
DOI：
10.1016/j.ijantimicag.2020.106202
发表时间：
2020-12
影响因子：
10.8
作者：
Gendrot M;Andreani J;Duflot I;Boxberger M;Le Bideau M;Mosnier J;Jardot P;Fonta I;Rolland C;Bogreau H;Hutter S;La Scola B;Pradines B
通讯作者：
Pradines B
影响因子：
8.4
作者：
Gendrot, Mathieu;Duflot, Isabelle;Pradines, Bruno
通讯作者：
Pradines, Bruno
影响因子：
13
作者：
Bakhiet M;Taurin S
通讯作者：
Taurin S
影响因子：
1.3
作者：
Alamdari, Daryoush Hamidi;Moghaddam, Ahmad Bagheri;Yarahmadi, Amir
通讯作者：
Yarahmadi, Amir